Target intelligence / Profile preview

UL16-binding protein 4 (ULBP4)

Target
ULBP4
Molecular classification
MHC class I-related protein, Receptor ligand, Type I transmembrane protein
01

Overview

UL16-binding protein 4 (ULBP4), also known as RAET1E, is a member of the RAET1 family of MHC class I-related proteins that serves as a stress-induced ligand for the activating receptor NKG2D (KLRK1) [3, 7]. Unlike many other ULBPs that are glycosylphosphatidylinositol (GPI)-anchored, ULBP4 is a type I transmembrane protein expressed predominantly in the skin, trachea, and certain tumors [4, 10]. Its primary biological function is to alert the immune system to cellular distress, malignancy, or viral infection, thereby triggering natural killer (NK) cell and T cell-mediated cytotoxicity [11, 13]. In oncology, ULBP4 is frequently upregulated in various cancers, including colorectal, ovarian, and liver carcinomas, making it a key component for immune recognition [14, 15]. However, its therapeutic utility is complicated by tumor escape mechanisms, such as the proteolytic shedding of ULBP4 into a soluble form that acts as a decoy and downregulates the NKG2D receptor [8, 11]. Beyond cancer, ULBP4 has been identified as a factor in the neuroinflammatory pathology of multiple sclerosis, where it is upregulated by astrocytes and enhances proinflammatory CD8+ T cell activities [6, 8]. Due to its restricted expression in healthy tissues and high expression in many cancers, it is an active target for development in adoptive cell therapies, particularly NKG2D-based chimeric antigen receptor (CAR) T cells [12, 16].

Other names
Retinoic acid early transcript 1ERAET1EN2DL-4LETALLymphocyte effector toxicity activation ligandNKG2DL4RAE-1-like transcript 4
02

Mechanism of action

Binds and activates the NKG2D (KLRK1) receptor on natural killer cells and CD8+ T cells to trigger cytotoxic activity and cytokine production.

03

Biological functions

Immune responseNatural killer cell activationT cell costimulationTumor surveillancePathogen recognition
04

Disease associations

CancerInfectionAutoimmune diseaseInflammationMultiple sclerosis
05

Safety considerations

Immune evasion via proteolytic sheddingPotential off-target effects in healthy skin or respiratory tissuesEnhancement of neuroinflammation in central nervous system disorders
06

Interacting drugs

CYAD-01

3 more in the full profile.

07

Biomarkers

Soluble ULBP4 (sULBP4) in cerebrospinal fluidULBP4 surface protein expressionULBP4 mRNA levels

Beyond the preview

Go deeper on UL16-binding protein 4 (ULBP4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on UL16-binding protein 4 (ULBP4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call